A monthly recap of the GenomeWeb Top 40 showed life science tools and diagnostics stocks gaining more quickly than broader indices in July, with CareDx posting the largest gain. The roundup also highlighted takeover dynamics at Seer and a multi-year technology collaboration involving 10x Genomics. Seer’s shares jumped amid competing bids from an investor group and its chairman/CEO, with both sides raising offers and the board rejecting all proposals to date. Separately, 10x Genomics reported a multi-year collaboration with Switzerland’s Lausanne University Hospital using its Flex Apex and Xenium platforms to identify tumor biomarkers. The update illustrates how market attention continues to cluster around reimbursement-relevant test coverage, revenue trajectory updates, and strategic technology partnerships. It also shows that diagnostics and proteomics names remain sensitive to deal talk and corporate governance developments. For biotech operators, the trading moves serve as a signal of where capital is still concentrated across enabling technologies and clinical diagnostics execution.